A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

Clinical trial NCT05194072 · TERMINATED

Trial details

NCT number: NCT05194072
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Ovarian Neoplasms Peritoneal Neoplasms Fallopian Tube Neoplasms Triple Negative Breast Neoplasms HER2 Negative Breast Neoplasms Hormone Receptor Positive Breast Neoplasms Endometrial Neoplasms Carcinoma, Non-Small-Cell Lung Cholangiocarcinoma Gallbladder Carcinoma Adenoid Cystic Carcinoma

Start date: 2022-01-12
Primary completion: 2025-05-14
Enrollment: 250

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.